… The primary objective of the study was to assess the correlation of the selected polymorphisms
with PFS. Secondary objectives were the correlations with OS and ORR. The Local Ethics …

… showed that the correlation between the vascular side-effect and the clinical outcome was
uncertain, since the development of bevacizumab-induced hypertension was inconsistently …

… with bevacizumab, as first-line treatment for metastatic colorectal … Arterial hypertension
correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab…

… with clinical outcome in metastatic colorectal cancer patients … at diagnosis had bevacizumab
as part of first-line therapy. … support looking further into this correlation with the creation of a …

… -EGFR; no indication for bevacizumab due to uncontrolled arterial hypertension and/or …
correlation between plasma VEGF-A and outcomes in mCRC patients treated with bevacizumab …

… for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become
a standard treatment option in combination with chemotherapy for patients with mCRC. …

… with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment
outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) …

… Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of
metastatic colorectal cancer … most strongly correlated with response to bevacizumab. It also …

… of bevacizumab-related side effects in patients affected by advanced colorectal cancer and
… concluded that elderly patients receiving bevacizumab with first-line chemotherapy showed …

… During first-line treatment, 90% of patients … ), pulmonary embolism (PE) and thrombophlebitis.
However, the added risk of bevacizumab to VTEs is ambiguous, since cancer patients are …